Media Centre

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

Monday April 22, 2024

Press Releases

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

Monday April 22, 2024

Emactuzumab designated as an Orphan Medicinal Product in Europe

Wednesday August 31, 2022

SynOx Therapeutics to present two posters at CTOS 2021 virtual Annual Meeting

Friday November 12, 2021

SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer

Tuesday August 3, 2021

SynOx Therapeutics Strengthens Team with appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer

Tuesday July 27, 2021

SynOx Therapeutics raises €37M in Series A Financing

Friday December 4, 2020

Publications

Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour

Tuesday December 1, 2020

CSF1R inhibition with emactuzumab in locally advanced diff use-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

Monday July 13, 2015

Events